Brief: Compass Pathways Says FDA Granted NDA Rolling Review Request & Awarded Commissioner's National Priority Voucher
24/04/2026 17:28
April 24 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS ANNOUNCES FDA GRANTED NDA ROLLING REVIEW REQUEST AND AWARDED COMMISSIONER'S NATIONAL PRIORITY VOUCHER COMPASS PATHWAYS PLC - AWARDED CNPV FOR COMP360 FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - CNPV PROGRAM PROVIDES SHORTENED 1-2 MONTH REVIEW TIME AFTER NDA FILING Source text: ID:nBwc808GGa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications